STOCK TITAN

AMRS Stock Price, News & Analysis

AMRS NASDAQ

Company Description

Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.

Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.

Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.

Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.

More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.

Stock Performance

$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding

SEC Filings

No SEC filings available for AMRS.

Financial Highlights

Revenue (TTM)
Net Income (TTM)
Diluted EPS (TTM)
Operating Cash Flow
Net Profit Margin
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What does Amyris, Inc. specialize in?

Amyris, Inc. specializes in synthetic biotechnology, converting plant sugars into sustainable ingredients for various markets, including Clean Health & Beauty and Flavors & Fragrances.

What is the Lab-to-Market™ technology platform?

The Lab-to-Market™ technology platform is Amyris' proprietary system that utilizes machine learning, robotics, and AI to rapidly bring new sustainable innovations to market at commercial scale.

Who is the current CEO of Amyris?

As of June 2023, Han Kieftenbeld is the Interim Chief Executive Officer of Amyris, while also serving as the company's Chief Financial Officer.

What recent strategic changes has Amyris implemented?

Amyris commenced voluntary Chapter 11 proceedings to restructure its operations and financial framework, aiming to improve its cost structure and liquidity while focusing on core R&D and commercialization competencies.

How is Amyris supporting its operations during the restructuring?

Amyris secured $190 million in debtor-in-possession financing from Foris Ventures to support daily operations and meet commitments during the restructuring process.

What is Amyris' 'Fit-to-Win' initiative?

'Fit-to-Win' is a cost reduction initiative aimed at optimizing Amyris' operational expenses and achieving cost savings of approximately $250 million.

Will Amyris continue to operate its consumer brands?

While Amyris plans to exit from its consumer brands and market them for sale, it will continue to operate these brands through retail and e-commerce platforms during the transition.

What is the impact of Amyris' products on the market?

Amyris' sustainable ingredients are included in over 20,000 products from top global brands, reaching more than 300 million consumers.

How can stakeholders get more information about Amyris' restructuring?

Stakeholders can find additional information on the restructuring at https://cases.stretto.com/Amyris or contact the dedicated helpline for vendors.

Where can I find more information about Amyris?

More information about Amyris can be found on their official website at http://www.amyris.com.